Literature DB >> 11137281

Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.

I Elman1, M N D'Ambra, S Krause, H Breiter, M Kane, R Morris, L Tuffy, D R Gastfriend.   

Abstract

This study explored the acute and long-term consequences of ultrarapid opioid detoxification (URD) in individuals with opioid dependence. In an open case series, seven patients underwent URD and subsequent treatment with daily naltrexone. Structured interviews, integrated rehabilitation and hair sampling were employed in the 12-week course of longitudinal follow-up. Cardiac and pulmonary physiology did not change significantly during the anesthesia phase of URD, but plasma ACTH and cortisol levels increased 15- and 13-fold, respectively. Marked withdrawal and tachypnea in all patients and respiratory distress in one patient occurred during the acute post-anesthesia phase. Withdrawal scores were significantly elevated for 3 weeks compared with baseline in the face of minimal self-reported craving for opioids. Anxiety, depression and vegetative symptoms improved gradually. Four patients remained abstinent of opioid use, two reported a brief period of opioid intake and one relapsed into daily opioid consumption. Given its effect on breathing and stress hormones, this procedure should be conducted by experienced anesthesiologists. The fact that URD and subsequent naltrexone treatment appears to cause a dissociation effect in the usual relationship between withdrawal and craving has implications for behavioral pharmacology. Further research is needed on the efficacy, safety, mechanisms and neurobiological sequelae of the procedure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137281     DOI: 10.1016/s0376-8716(00)00139-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

Review 2.  Pain and suicidality: insights from reward and addiction neuroscience.

Authors:  Igor Elman; David Borsook; Nora D Volkow
Journal:  Prog Neurobiol       Date:  2013-07-01       Impact factor: 11.685

Review 3.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

4.  Is There an Association Between Salivary Cortisol and Dropping Out of Inpatient Substance Addiction Treatments? A Prospective Repeated Measures Study.

Authors:  Kari Bøhle; Eli Otterholt; Stål Bjørkly
Journal:  Subst Abuse       Date:  2022-06-29

Review 5.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

6.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

7.  Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.

Authors:  A-L Wang; I Elman; S B Lowen; S J Blady; K G Lynch; J M Hyatt; C P O'Brien; D D Langleben
Journal:  Transl Psychiatry       Date:  2015-03-17       Impact factor: 6.222

8.  Six-month follow-up study of ultrarapid opiate detoxification with naltrexone.

Authors:  Mohammad Forozeshfard; Babak Hosseinzadeh Zoroufchi; Mohammad Bagher Saberi Zafarghandi; Razieh Bandari; Behzad Foroutan
Journal:  Int J High Risk Behav Addict       Date:  2014-09-17

9.  Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report.

Authors:  Laurence Lalanne; Chloe Nicot; Jean-Philippe Lang; Gilles Bertschy; Eric Salvat
Journal:  BMC Psychiatry       Date:  2016-11-10       Impact factor: 3.630

10.  Ultrarapid opioid detoxification: current status in iran and controversies.

Authors:  Seyyed Mojtaba Yassini Ardekani; Sara Yassini Ardekani
Journal:  Int J High Risk Behav Addict       Date:  2013-12-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.